本文選題：右歸丸加減方 + 肝腎虧虛骨質疏松癥　； 參考：《黑龍江中醫(yī)藥大學》2017年碩士論文

【摘要】：目的:觀察右歸丸加減方治療骨質疏松癥的臨床療效,并與珍牡腎骨膠囊治療骨質疏松癥進行對比,從而引出右歸丸加減方治療骨質疏松的作用機理,探討中醫(yī)中藥治療骨質疏松癥的缺點及不足,從而豐富骨質疏松癥臨床用藥。方法:本研究在中醫(yī)辨證論治、整體觀念的指導下對肝腎虧虛型骨質疏松癥患者服用右歸丸加減方、珍牡腎骨膠囊后的臨床療效進行了細致的研究。將符合納入標準的患者(60人)隨機分為治療組(30人),對照組(30人)。治療組給予右歸丸加減方,患者每次服用1丸,每日服用2次。早晚溫水送服。對照組給予珍牡腎骨膠囊1粒日三次口服。連續(xù)服用兩個月,觀察患者病情。在觀察試驗開始前,分別詳細記錄每個患者臨床癥候、骨密度情況波動變化,統(tǒng)計用藥后患者治愈率及用藥半年后患者中醫(yī)癥候反彈情況。結果:記錄數(shù)據(jù)提示:在觀察試驗之前臨床癥候、骨密度情況波動變化經統(tǒng)計學分析后無明顯差異,說明兩組可比性大。治療組與對照組分別服用右歸丸加減方與珍牡腎骨膠囊3個月后,再次詳細記錄每個患者臨床癥候、骨密度情況波動變化。記錄數(shù)據(jù)提示:在觀察試驗之后臨床癥候變化幅度較大,統(tǒng)計學意義明顯,骨密度情況變化幅度無明顯差異。結論:通過數(shù)據(jù)分析可推測,右歸丸加減方與珍牡腎骨膠囊在肝腎虧虛骨折疏松癥患者治療上都具有一定的療效,且治療組優(yōu)于對照組。但兩種藥物都具有一定的失訪率,且失訪患者都為嚴重骨質疏松患者�？赏茰y對于嚴重的骨質疏松患者的治療,單獨使用右歸丸加減方或珍牡腎骨膠囊的療效不佳,對于嚴重骨質疏松癥的治療結果不佳,應聯(lián)合用藥,輔助其他治療方案。討論部分對右歸丸治療骨質疏松癥的藥物機理進行了初步討論,對本文選用的方劑劑型進行了分析,對于中醫(yī)癥型對于骨質疏松癥的中醫(yī)癥狀評分做出了思考,最后提出本次觀察存在的不足,對中醫(yī)特色治療骨質疏松癥結果做出肯定。
[Abstract]:Objective: to observe the clinical effect of Yougui Pill plus decoction in treating osteoporosis, and to compare it with Zhenmushengu capsule in the treatment of osteoporosis, so as to elicit the mechanism of the treatment of osteoporosis by adding and reducing prescription of Yougui Pill. To explore the shortcomings and deficiencies of traditional Chinese medicine (TCM) in the treatment of osteoporosis, so as to enrich the clinical use of Osteoporosis. Methods: under the guidance of TCM syndrome differentiation and holistic concept, the clinical efficacy of Zhenmu Shengu capsule (JMC) in patients with osteoporosis due to deficiency of liver and kidney was studied. 60 patients who met the inclusion criteria were randomly divided into treatment group (30 patients) and control group (30 patients). The treatment group was given the right Gui Pill plus or minus prescription, the patient took 1 pill twice a day. Morning and evening warm water delivery clothes. The control group was given Zhenmu Shengu capsule 3 times a day. Take it continuously for two months and observe the patient's condition. Before the beginning of the observation test, the clinical symptoms and bone mineral density of each patient were recorded in detail, and the cure rate of the patients and the rebound of TCM symptoms after half a year treatment were counted. Results: the recorded data showed that there was no significant difference between the two groups after statistical analysis of clinical symptoms and bone mineral density fluctuation, which indicated that the two groups were comparable. The treatment group and the control group were treated with Yougui Pill and Zhenjiangshengu capsule for 3 months. The clinical symptoms and bone mineral density of each patient were recorded in detail again. The results showed that the changes of clinical symptoms and bone mineral density were larger and statistically significant after the observation of the test. Conclusion: according to the analysis of data, it can be inferred that Yougui Pill plus subtraction prescription and Zhenzhen Mushengu capsule have certain curative effect on the patients with deficiency of liver and kidney fracture and osteoporosis, and the treatment group is superior to the control group. However, both drugs have a certain rate of loss of visits, and both of them are patients with severe osteoporosis. It can be inferred that for the treatment of severe osteoporosis patients, the curative effect of Yougui Pill or Zhenmushengu capsule alone is not good, and the treatment result of severe osteoporosis should be combined with other treatment schemes. In the part of discussion, the drug mechanism of Yougui Pill in treating osteoporosis was discussed, the formulation of prescription was analyzed, and the TCM symptom score of TCM syndrome type for osteoporosis was considered. Finally, the shortcomings of this observation are pointed out, and the results of TCM characteristic treatment of osteoporosis are confirmed.
【學位授予單位】：黑龍江中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R259

【參考文獻】

相關期刊論文 前10條

1 張芳;郭盛;錢大瑋;張霞;段金廒;;枸杞子中多類型小分子化學物質研究開發(fā)現(xiàn)狀及前景分析[J];中藥材;2016年12期

2 李艷;苗明三;;肉桂的化學、藥理及應用特點[J];中醫(yī)學報;2015年09期

3 馮晗;周宏灝;歐陽冬生;;杜仲的化學成分及藥理作用研究進展[J];中國臨床藥理學與治療學;2015年06期

4 王玲;曾祥文;周峰;李文竹;;探討運動量與骨質疏松的發(fā)病關系[J];中國療養(yǎng)醫(yī)學;2015年04期

5 張婧卓;林U，

本文編號：2060103